
Knnate Biopharma (KNTE) Stock Forecast & Price Target
Knnate Biopharma (KNTE) Analyst Ratings
Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 14%
Hold 43%
Sell 0%
Strong Sell 0%
Knnate Biopharma (KNTE) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 14% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Knnate Biopharma and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Knnate Biopharma and is not a guaranteed prediction by Public.com or investment advice.
Knnate Biopharma (KNTE) Analyst Forecast & Price Prediction
Get the latest Knnate Biopharma (KNTE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Knnate Biopharma (KNTE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Knnate Biopharma (KNTE) Forecast
Analysts have given Knnate Biopharma (KNTE) a Buy based on their latest research and market trends.
According to 7 analysts, Knnate Biopharma (KNTE) has a Buy consensus rating as of Jun 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $16.08, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $16.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.